{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:47:11Z","timestamp":1785869231017,"version":"3.56.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.semradonc.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:03:18Z","timestamp":1733983398000},"page":"57-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of Radiotherapy in the Management of Elderly Patients With Lymphoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Ritesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2024.08.003_bib0001","unstructured":"World Health Organization, Ageing and health: WHO Fact Sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0002","first-page":"34","article-title":"Lymphoma: diagnosis and treatment","volume":"101","author":"Lewis","year":"2020","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0003","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0004","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1634\/theoncologist.2011-0214","article-title":"Second malignancies among elderly survivors of cancer","volume":"16","author":"VanderWalde","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0006","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/ecc.12302","article-title":"Expert consensus panel guidelines on geriatric assessment in oncology","volume":"24","author":"O'Donovan","year":"2015","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/ageing\/aft032","article-title":"Time trends of incidence of age-associated diseases in the US elderly population: medicare-based analysis","volume":"42","author":"Akushevich","year":"2013","journal-title":"Age Ageing"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2006.1.295","article-title":"Optimal use of prognostic factors in non-Hodgkin lymphoma","volume":"6","author":"Sehn","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0009","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.19.02809","article-title":"Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review","volume":"38","author":"DuMontier","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0010","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International society of geriatric oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0011","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jgo.2019.04.016","article-title":"A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer","volume":"10","author":"van Walree","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0013","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.critrevonc.2006.11.001","article-title":"Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale","volume":"61","author":"Wedding","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large b-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0016","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/CCO.0000000000000555","article-title":"Follicular lymphomas in vulnerable\/older patients","volume":"31","author":"Tucci","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0017","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN guidelines\u00ae insights: B-Cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0018","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0019","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/cncr.29491","article-title":"What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?","volume":"121","author":"Vargo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0021","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0022","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.2112","article-title":"Response-adapted ultralow-dose radiation therapy for orbital indolent B-Cell lymphoma: a phase 2 nonrandomized controlled trial","author":"Pinnix","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0024","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","article-title":"Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study","volume":"94","author":"Ruella","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0026","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s13063-019-3614-y","volume":"20","author":"K\u00f6nig","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0027","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2022-160246","article-title":"Big boom\u201d (4 Gy x 1) radiation treatment (RT) versus \u201cbig boom\u201d (2 Gy x 2) for Non-Hodgkin lymphoma (NHL)","volume":"140","author":"Hajj","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0028","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3390\/cancers14071742","article-title":"Extranodal marginal zone lymphoma: pathogenesis, diagnosis and treatment","volume":"14","author":"Di Rocco","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0029","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2013.04.035","article-title":"Low-dose radiation therapy (2 Gy \u00d7 2) in the treatment of orbital lymphoma","volume":"86","author":"Fasola","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/hed.24717","article-title":"Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma","volume":"39","author":"Pinnix","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0031","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2022.07.2322","article-title":"Response adapted ultra low dose radiation therapy for the definitive management of orbital indolent B-Cell lymphoma","volume":"114","author":"Pinnix","year":"2022","journal-title":"Internat J Radiat Oncol Biolo Phys"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0032","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(24)00133-9","article-title":"Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial","volume":"11","author":"Gunther","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper","volume":"6","author":"Morrison","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0034","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.29290","article-title":"Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0035","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0036","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0037","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0038","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.13619","article-title":"Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0039","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2015.64.9418","article-title":"Re-examining the role of radiation therapy for diffuse large B-Cell lymphoma in the modern era","volume":"34","author":"Ng","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijrobp.2015.12.357","article-title":"Radiation therapy for diffuse large B-Cell lymphoma: indications, outcomes, and controversies","volume":"94","author":"Pinnix","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0042","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-Cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736","volume":"34","author":"Stephens","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0043","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","article-title":"Treatment selection and survival outcomes in early-stage diffuse large B-Cell lymphoma: do we still need consolidative radiotherapy?","volume":"33","author":"Vargo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0044","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2016.1205739","article-title":"Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy","volume":"58","author":"Parikh","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.adro.2017.04.004","article-title":"Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions","volume":"2","author":"Pinnix","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0046","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3109\/10428194.2016.1153088","article-title":"Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy","volume":"57","author":"Ciammella","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0047","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/10428194.2014.930853","article-title":"Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients","volume":"56","author":"Odejide","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0048","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0049","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large b-cell lymphoma: results of intergroup national clinical trials network study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0050","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0051","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0052","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0053","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijrobp.2019.02.055","article-title":"Phase 2 study of dose-reduced consolidation radiation therapy in diffuse large b-cell lymphoma","volume":"105","author":"Kelsey","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0054","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.25789","article-title":"Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma","volume":"95","author":"W\u00e4sterlid","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0055","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0056","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","article-title":"The concept and evolution of involved site radiation therapy for lymphoma","volume":"20","author":"Specht","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0057","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study","volume":"22","author":"Evens","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0058","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0059","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0959-8049(99)00267-1","article-title":"Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries","volume":"36","author":"Roy","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0061","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0062","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0063","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0064","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0065","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0066","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0067","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0068","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/annonc\/mdl379","article-title":"Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group","volume":"18","author":"Klimm","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0069","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0070","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.clml.2017.09.009","article-title":"Treatment patterns and outcomes in early-stage hodgkin lymphoma in the elderly: a national cancer database analysis","volume":"17","author":"Goyal","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0071","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0360-3016(02)04596-0","article-title":"Hodgkin's disease in elderly patients (>or =60): clinical outcome and treatment strategies","volume":"56","author":"Kim","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0072","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/annonc\/mdl094","article-title":"A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients","volume":"17","author":"Landgren","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0073","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0074","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0075","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)","volume":"23","author":"Johnson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0076","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0077","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase ii study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0078","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0079","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0080","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.semradonc.2024.08.003_bib0081","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.semradonc.2024.08.003_bib0082","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.3151","article-title":"Reappraisal of the role of radiation therapy in lymphoma treatment","volume":"41","author":"Specht","year":"2023","journal-title":"Hematol Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:59:32Z","timestamp":1734011972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429624000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1053429624000675"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.08.003","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Radiotherapy in the Management of Elderly Patients With Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}